Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

D-Ribose for Fatigue in Subjects With Fibromyalgia

ClinicalTrials.gov ID: NCT01315210

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01315210. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of D-Ribose in Subjects With Fibromyalgia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the safety and to determine the efficacy of D-ribose for the amelioration of fatigue in subjects with fibromyalgia. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center, multiple dose study of D-ribose versus placebo administered at doses of 5 g three times a day (TID) over a 12-week period to subjects who are experiencing fatigue associated with a diagnosis of fibromyalgia.

Study identification

NCT ID
NCT01315210
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
RiboCor, Inc.
Industry
Enrollment
110 participants

Conditions and interventions

Conditions

Interventions

Drug · Dietary Supplement

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2011 (Type not available)
Primary completion
Oct 2012 (Actual)
Completion
Oct 2012 (Actual)
Last update posted
Sep 18, 2013

2011 – 2012

United States locations

U.S. sites
9
U.S. states
6
U.S. cities
9
Facility City State ZIP Site status
Superior Research, LLC Sacramento California 95825 —
Avail Clinical Research DeLand Florida 32720 —
Renstar Medical Research Ocala Florida 34471 —
University of Kentucky Lexington Kentucky 40536 —
Columbia Medical Practice Columbia Maryland 21045 —
The Center for Rheumatology and Bone Research Wheaton Maryland 20902 —
Peters Medical Research High Point North Carolina 27262 —
Wake Research Associates, LLC Raleigh North Carolina 27612 —
Altoona Center for Clinical Research Duncansville Pennsylvania 16635 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01315210, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 18, 2013 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.